| Autor: |
Prabhat Bhargava, Narmadha Rathnasamy, Ramnath Shenoy, Seema Gulia, Jyoti Bajpai, Jaya Ghosh, Sushmita Rath, Ashwini Budrukkar, Tanuja Shet, Asawari Patil, Sangeeta Desai, Nita Nair, Shalaka Joshi, Palak Popat, Tabassum Wadasadawala, Rima Pathak, Rajiv Sarin, Sadhana Kannan, Rajendra Badwe, Sudeep Gupta |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
JCO Global Oncology, Vol , Iss 8 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2687-8941 |
| DOI: |
10.1200/GO.22.00126 |
| Popis: |
PURPOSEThere are sparse data in patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer with brain metastases from real-world settings, especially where access to newer targeted therapies is limited.METHODSThis was a single institution, retrospective cohort study of patients with HER2-positive breast cancer diagnosed between January 2013 and December 2017 to have brain metastases and treated with any HER2-targeted therapy. The main objectives were to estimate progression-free survival (PFS) and overall survival (OS) from the time of brain metastases.RESULTSA total of 102 patients with a median age of 52 (interquartile range, 45-57) years were included, of whom 63 (61.8%) had received one line and 14 (13.7%) had received two lines of HER2-targeted therapies before brain metastasis, 98 (96.1%) were symptomatic at presentation, 22 (25.3%) had solitary brain lesion, 22 (25.3%) had 2-5 lesions, and 43 (49.4%) had ≥ 5 lesions. Local treatment included surgical resection in nine (8.9%) and radiotherapy in all (100%) patients. The first HER2-targeted therapy after brain metastasis was lapatinib in 71 (68.6%), trastuzumab in 19 (18.6%), lapatinib and trastuzumab in three (2.9%), trastuzumab emtansine in four (3.9%), and intrathecal trastuzumab in five (4.9%) patients. At a median follow-up of 13.9 months, the median PFS and OS were 8 (95% CI, 6.2 to 9.8) months and 14 (95% CI, 10.8 to 17.2) months, respectively, with a 2-year OS of 25% (95% CI, 16.7 to 34.4). The median PFS in patients who received lapatinib-capecitabine regimen (n = 62) was 9.0 (95% CI, 7.3 to 10.7) months.CONCLUSIONThere was a substantial clinical benefit of local and systemic therapy in patients with brain metastases and HER2-positive disease in a real-world setting with limited access to newer HER2-targeted drugs. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
